VolitionRX (NYSEAMERICAN:VNRX) Releases Quarterly Earnings Results, Beats Estimates By $0.17 EPS

VolitionRX (NYSEAMERICAN:VNRX) announced its quarterly earnings data on Thursday. The medical research company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.17, FiscalAI reports. The company had revenue of $1.61 million during the quarter, compared to analysts’ expectations of $0.71 million.

VolitionRX Price Performance

NYSEAMERICAN:VNRX traded down $0.02 during midday trading on Thursday, hitting $0.18. The company’s stock had a trading volume of 857,984 shares, compared to its average volume of 2,845,635. VolitionRX has a fifty-two week low of $0.16 and a fifty-two week high of $7.90. The firm’s 50 day moving average is $0.24 and its 200-day moving average is $1.97. The firm has a market cap of $2.52 million, a P/E ratio of -0.05 and a beta of 1.16.

Wall Street Analysts Forecast Growth

Separately, Benchmark reissued a “hold” rating on shares of VolitionRX in a research report on Monday, August 17th. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.00.

About VolitionRX

VolitionRx Limited is a biotechnology company developing blood-based diagnostic tests intended to support the early detection and management of disease. Its technology platform, Nu.Q, analyzes nucleosomes—small structures released into the bloodstream when cells die—to identify biological signals associated with cancer and other conditions. The company’s products and development programs serve human and veterinary health markets. Its Nu.Q Vet platform is designed to help veterinarians screen for and monitor cancer in companion animals, while the company is also developing Nu.Q-based applications for human cancer, infectious diseases, and other medical conditions.